News Alert: Moderna says its coronavirus vaccine triggers immune response in teens ages 12 to 17; company will seek FDA authorization next month

Biotechnology company Moderna announced Tuesday that its two-shot coronavirus vaccine produced the same immune response in teenagers as adults, and it plans to submit the data to U.S. regulators in early June. If authorized, the vaccine would become the second available for adolescents as young as 12. Pfizer-BioNTech's vaccine was authorized for that age group earlier this month. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Sign up for alerts News Alert May 25, 8:48 a.m. EDT Moderna says its coronavirus vaccine triggers immune response in teens ages 12 to 17; company will seek FDA authorization next month Biotechnology company Moderna announced Tuesday that its two-shot coronavirus vaccine produced the same immune response in teenagers as adults, and it plans to submit the data to U.S. regulators in early June. If authorized, the vaccine would become the second available for adolescents as young as 12. Pfizer-BioNTech's vaccine was authorized for that age group earlier this month. Read more   Advertisement

Manage my email newsletters and alerts | Unsubscribe | Privacy Policy | Help You received this email because you signed up for news alerts or because it is included in your subscription. ©2021 The Washington Post | 1301 K St NW, Washington DC 20071